“Current cash backing likely sits around $20 million but considering cash burn and trial close-out costs we see Percheron ...

Public health authorities in the Eastern Townships are investigating after multiple ALS cases were reported in the same area.

Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a ...

Neurologists have grappled with a cluster of amyotrophic lateral sclerosis cases in France, where a fondness for a toxic wild ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a phase ... upset at the onset of treatment than those who received ...

DAZALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to those who received ...

(Reuters) – Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal ...

spinal), site of spinal onset (upper limbs, lower limbs, upper and lower limbs, trunk), delay between symptom onset and diagnosis (DOD, 0–6, 7–12, 13–24 months, ≥25 months), body-mass ...

Sclerosis means “hardening of tissue,” and tubers are root-shaped growths. TS can be inherited or caused by spontaneous gene mutation. Some people only have mild symptoms, while others ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...

What is masitinib for ALS? Masitinib is an oral medication being developed by AB Science as a potential add-on treatment for slowing disease progression in people with amyotrophic lateral sclerosis ...